CAR-T细胞免疫在胸部恶性肿瘤中的研究进展  

Progress of Chimeric Antigen Receptor Gene Modified-T Cell Immunotherapy forThoracic Malignancies

作　　者：陈富坤 陈娜娜 邓智勇 吕娟 覃雯静 朱家伦 CHEN Fukun;CHEN Nana;DENG Zhiyong;LYU Juan;QIN Wenjing;ZHU Jialun(Department of Nuclear Medicine,Yunnan Cancer Hospital,the Third Affiliated Hospital of Kunming Medical University,Kunming 650118,China;Department of SICU,The Second Affiliated Hospital of Kunming Medical University,Kunming 650101,China)

机构地区：[1]云南省肿瘤医院,昆明医科大学第三附属医院核医学科,昆明650118 [2]昆明医科大学第二附属医院重症监护病房,昆明650101

出　　处：《肿瘤防治研究》2023年第10期1010-1014,共5页Cancer Research on Prevention and Treatment

基　　金：国家自然科学基金(82160343);云南省科技厅-昆明医科大学应用基础研究联合专项面上项目(202301AY070001-246)。

摘　　要：随着对胸部恶性肿瘤发病机制及其病理生理学的全面理解,其治疗从外科手术、放化疗逐步向个体化精准靶向治疗和免疫治疗转变。嵌合抗原受体基因修饰T(CAR-T)细胞作为一种抗肿瘤免疫疗法,已有5款CAR-T产品经美国FDA批准用于血液系统恶性肿瘤治疗,同时也在实体肿瘤中取得了很好的治疗效果。然而,目前CAR-T细胞免疫疗法在胸部恶性肿瘤治疗中仍面临重大挑战。本文总结了CAR-T细胞免疫疗在胸部恶性肿瘤治疗中的最新研究进展,包括CAR-T细胞的基本特征、热门靶标抗原、存在的问题及挑战等,以期为胸部恶性肿瘤的临床免疫治疗提供新思路和策略。With a deepened understanding of the pathophysiology and pathogenesis of thoracic malignancies,the treatment has been transited from traditional treatment on the basis of surgery,radiotherapy,and chemotherapy to individualized and precise targeted therapy and immunotherapy.As an antitumor immunotherapy,chimeric antigen receptor gene-modified T(CAR-T)cells have been approved by the FDA for the treatment of hematological malignancies in five CAR-T products.They have also achieved good therapeutic effects in solid tumors.However,significant challenges remain in the clinical application of CAR-T cell immunotherapy in thoracic malignancies.In this review,the latest research progress of CAR-T cell immunotherapy in the treatment of thoracic malignancies were summarized,including the basic characteristics of CAR-T cells,the popular target antigens,and the existing problems and challenges,to provide new ideas and strategies for clinical immunotherapy of thoracic malignancies.

关 键 词：胸部肿瘤 CAR-T 免疫疗法 抗原靶点 实体瘤 

分 类 号：R734[医药卫生—肿瘤]